Gyre Therapeutics
GYRE
Gyre Therapeutics (GYRE) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Jefferies | Initiated Coverage | Buy | $16.00 | Oct 10, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $18.00 | Aug 26, 2025 |
Frequently asked questions
What is the latest analyst rating on GYRE?
On Oct 10, 2025, Jefferies initiated coverage of Gyre Therapeutics at Buy with a price target of $16.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.